+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tuberculosis Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Treatment Regimen, Tuberculosis Type - Global Forecast to 2030- Product Image
Tuberculosis Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Treatment Regimen, Tuberculosis Type - Global Forecast to 2030- Product Image
Sale

Tuberculosis Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Treatment Regimen, Tuberculosis Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4985928
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers in pharmaceutical and healthcare organizations face unprecedented complexity and opportunity in the tuberculosis drugs market, driven by emerging therapeutics, regulatory shifts, and evolving economic landscapes. Positioning your strategy ahead of these changes demands a clear, data-driven understanding of the field’s trajectories.

Market Snapshot: Tuberculosis Drugs Market Size & Growth

The Tuberculosis Drugs Market grew from USD 2.04 billion in 2024 to USD 2.18 billion in 2025. It is expected to continue growing at a CAGR of 6.30%, reaching USD 2.95 billion by 2030. Ongoing scientific advances, shifts in disease burden, and new treatment regimens are propelling dynamic changes in market demand and fueling expansion. Close monitoring of policy changes and the competitive environment remains critical for sustainable growth in this sector.

Scope & Segmentation

This report provides a structured analysis of the tuberculosis drugs market, charting critical dimensions and segmentation factors essential for decision-making. Market coverage includes a comprehensive breakdown by product, distribution, use case, and regional influences.

  • Drug Class: First-line therapies, including single and fixed dose combinations; novel agents such as Bedaquiline, Delamanid, and Pretomanid; second-line drugs incorporating fluoroquinolones and injectable aminoglycosides.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacy networks, each serving distinct patient needs and therapeutic settings.
  • Route of Administration: Both injectable and oral options tailored to patient profiles and resource settings.
  • Treatment Regimen: Individualized, long-course, and short-course therapy models to match resistance patterns and patient contexts.
  • Tuberculosis Type: Pulmonary and extrapulmonary disease, supporting tailored diagnostic and treatment protocols.
  • Regional Scope: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (featuring major and emerging markets), and Asia-Pacific (encompassing China, India, Japan, and other high-burden countries).
  • Covered Companies: Johnson & Johnson, Lupin Limited, Cipla Limited, Viatris Inc, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Limited, Teva Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, and F. Hoffmann-La Roche Ltd.

Tuberculosis Drugs Market: Key Takeaways

  • Multiple drug-resistant strains are redefining research priorities, increasing emphasis on novel molecule development and rapid clinical adoption in advanced pipelines.
  • Personalized treatment regimens and integrated fixed dose combinations are central to improved adherence and more effective disease management in complex cases.
  • Shifting global supply chain strategies highlight a heightened focus on production agility and risk mitigation in response to recent disruptions and evolving demand landscapes.
  • Innovative public-private partnerships and adaptive reimbursement policies are accelerating patient access to the latest therapies in both established and emerging markets.
  • Expansion of digital adherence monitoring and real-world evidence generation are fast becoming critical differentiators for leading players and new entrants alike.
  • Regional policy differences demand targeted go-to-market approaches tailored to specific reimbursement environments and market access criteria.

Tariff Impact: Navigating US 2025 Policies

New US tariffs set for 2025 are restructuring trade flows for tuberculosis drugs. Cost-driven generic imports and fixed dose formulations historically maintained low tariffs to sustain access in sensitive regions. The revised tariff regime is intensifying cost pressures and challenging procurement practices particularly in high-burden countries. In response, pharmaceutical companies are adjusting manufacturing footprints, investing in supplier diversification, and establishing more resilient sourcing models. Public procurement agencies are re-evaluating their strategies, weighing cost containment against the need for innovative differentiation, and shaping the competitive landscape for years to come.

Methodology & Data Sources

This analysis draws on a combination of primary and secondary research methods. Expert interviews with stakeholders across clinical, procurement, and policy domains provide qualitative context, while rigorous review of regulatory submissions, clinical registries, and patent data ensure quantitative accuracy. Additional insights are derived from procurement databases and financial disclosures, validating segmentation and geographic trends through cross-checked data layers.

Why This Report Matters

  • Equips executive decision-makers with actionable insights to inform investment, procurement, and go-to-market strategies in a rapidly changing environment.
  • Identifies actionable supply chain and regulatory levers for mitigating risk and enhancing market resilience.
  • Delivers structured intelligence on segmentation, channel evolution, and leading competitors to clarify tactical opportunities and benchmark progress in critical regions.

Conclusion

With the tuberculosis drugs market entering a new era of innovation and operational complexity, leaders must act decisively to align with evolving dynamics. Strategic insight and operational agility will be essential in advancing patient care and realizing sustainable growth in this sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tuberculosis Drugs Market, by Drug Class
8.1. Introduction
8.2. First Line
8.2.1. Fixed Dose Combination
8.2.1.1. Four Drug Combination
8.2.1.2. Three Drug Combination
8.2.1.3. Two Drug Combination
8.2.2. Single Drug Preparations
8.3. Novel
8.3.1. Bedaquiline
8.3.2. Delamanid
8.3.3. Pretomanid
8.4. Second Line
8.4.1. Fluoroquinolones
8.4.2. Injectable Aminoglycosides
9. Tuberculosis Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Tuberculosis Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
11. Tuberculosis Drugs Market, by Treatment Regimen
11.1. Introduction
11.2. Individualized Regimen
11.3. Long Course
11.4. Short Course
12. Tuberculosis Drugs Market, by Tuberculosis Type
12.1. Introduction
12.2. Extrapulmonary
12.3. Pulmonary
13. Americas Tuberculosis Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Tuberculosis Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Tuberculosis Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Johnson & Johnson
16.3.2. Lupin Limited
16.3.3. Cipla Limited
16.3.4. Viatris Inc
16.3.5. Sun Pharmaceutical Industries Limited
16.3.6. Otsuka Pharmaceutical Co., Ltd.
16.3.7. Dr. Reddy’s Laboratories Limited
16.3.8. Teva Pharmaceutical Industries Limited
16.3.9. Glenmark Pharmaceuticals Limited
16.3.10. F. Hoffmann-La Roche Ltd
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TUBERCULOSIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. TUBERCULOSIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. TUBERCULOSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FOUR DRUG COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY THREE DRUG COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TWO DRUG COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SINGLE DRUG PREPARATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DELAMANID, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PRETOMANID, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 60. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 61. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 62. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 63. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 66. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 75. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 113. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 116. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 117. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 118. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 121. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 125. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 126. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 127. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 130. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 140. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 142. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 143. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 144. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 145. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 148. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 149. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 151. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 152. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 153. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 154. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 157. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 185. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 187. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 188. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 189. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 190. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 193. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 203. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 205. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 206. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 207. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 208. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 211. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 212. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 214. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 215. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 216. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 217. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 220. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 239. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 241. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 242. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 243. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 244. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 247. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 248. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 250. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 251. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 252. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 253. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 256. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 266. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 267. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 268. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 269. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 270. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 271. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 274. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 275. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 276. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 277. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 278. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 279. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 280. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 283. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 284. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 303. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 304. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 305. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 306. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 307. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 308. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 311. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 312. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 314. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 315. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 316. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 317. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 320. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 321. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 323. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 324. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 325. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 326. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 329. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 341. SOUTH

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tuberculosis Drugs market report include:
  • Johnson & Johnson
  • Lupin Limited
  • Cipla Limited
  • Viatris Inc
  • Sun Pharmaceutical Industries Limited
  • Otsuka Pharmaceutical Co., Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Teva Pharmaceutical Industries Limited
  • Glenmark Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.18 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.95 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 178 Pages
  • Global
From
Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Tuberculosis Treatment Drugs - Global Strategic Business Report - Product Image

Tuberculosis Treatment Drugs - Global Strategic Business Report

  • Report
  • 369 Pages
  • Global
From
Tuberculosis Therapeutics - Global Strategic Business Report - Product Image

Tuberculosis Therapeutics - Global Strategic Business Report

  • Report
  • 283 Pages
  • Global
From

About the Tuberculosis Drug Market

The Tuberculosis Drug market is a subset of the larger Respiratory Drug market. It is composed of drugs used to treat tuberculosis, a bacterial infection that affects the lungs and other parts of the body. These drugs are typically antibiotics, such as isoniazid, rifampicin, and ethambutol, and are used in combination to treat the infection. The drugs are usually taken for a period of six to nine months, and are often used in combination with other treatments, such as surgery or chemotherapy. The Tuberculosis Drug market is highly competitive, with many companies offering different combinations of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Sanofi, Merck, and Novartis. Other companies, such as Cipla, Lupin, and Sun Pharmaceuticals, also offer a range of tuberculosis drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.